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The symptoms of schizophrenia have been categorized into three subsets 
including positive, negative, and cognitive symptoms. Although atypical antipsychotic 
use has shown promising reduction in positive and negative symptoms of 
schizophrenia, such as hallucination, delusions and flat affect, the cognitive subset of 
symptoms remains and has an adverse impact on those affected. Chronic treatment 
with the atypical/secondary antipsychotic clozapine is one example that has ameliorated 
hallucinations and delusions but results in cognitive memory deficits. When chronically 
given in conjunction with the HDAC inhibitor, SAHA, the cognitive memory deficits of 
mouse models decline. HDAC2KO mice were bred and used in chronic treatments with 
either vehicle or SAHA and compared to WT mice, in order to analyze whether 
differential gene expression was occurring in an HDAC2 dependent manner. The 
expression of various genes involved in brain function were evaluated using RT-qPCR 
to determine potential differential regulation. The results showed differential expression 
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of the following genes:  Abhd16a, Gbf1, Itch, and Ube2g1. These genes are all involved 
in various neuronal functions. 
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Chapter 1:  Introduction 
1. Schizophrenia 
According to the National Institute of Mental Health, schizophrenia is a “chronic and 
severe mental disorder that affects how a person thinks, feels, and behaves”. 
Individuals with the disorder may seem that they have completely lost touch with 
reality. Symptoms typically begin between ages 16 and 30 and in some rare cases, 
the disorder can manifest in children as well. 
1.1. Clinical features of schizophrenia 
Symptoms of schizophrenia are typically categorized into three subsets including 
positive symptoms, negative symptoms, and cognitive symptoms (11, 13). 
1.1.1. Positive symptoms 
Positive symptoms are the presence of beliefs, behaviors, and sensations 
that would otherwise not occur normally. These symptoms include 
disturbances of thought processes, delusions, and hallucinations (11). 
1.1.2. Negative symptoms 
Negative symptoms refer to the lack of normal behaviors that are otherwise 
present in healthy individuals. These include differences in feelings, 
movements, and behavior (11). 
1.1.3. Cognitive symptoms 
Cognitive symptoms refer to problems such as disorganized thoughts, 
difficulty understanding, poor concentration and/or memory, or difficulty 
expressing thoughts, feelings, and behaviors (11). 
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Figure 1. Demographics of Schizophrenia (Reprinted from:  National Institute of 
Mental Health) 
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1.2. Treatment of Schizophrenia 
1.2.1. First generation/Primary antipsychotics 
Some examples of commonly used primary or first generation 
antipsychotic medications include chlorpromazine, fluphenazine, 
thioridazine, and haloperidol. These primary antipsychotics generally treat 
positive symptoms successfully, but have limited efficacy for the other two 
subsets of symptoms (11). Another negative result of these primary 
antipsychotics are their extrapyramidal side effects. Extrapyramidal side 
effects are commonly categorized as dystonia, dyskinesia, parkinsonism, 
and akathisia. Dystonia is described as abnormality of voluntary muscle 
tone or an abnormal degree of fixity associated with sustained muscular 
contraction. Similarly, dyskinesia describes impairment or the abnormality 
of voluntary movement. Parkinsonism refers to movement abnormalities 
usually associated with Parkinson’s disease such as tremor, slow 
movement, or impaired speech. Akathisia is another movement disorder 
categorized by an inner feeling of restlessness and compulsion to be in 
constant motion (21). 
1.2.2. Secondary/atypical antipsychotics - Atypical antipsychotics or secondary 
antipsychotic drugs include clozapine and risperidone. These drugs block 
both 5-HT2A (serotonin) receptors as well as D2 (dopamine) receptors. 
Clozapine is commonly used because of its effective treatment of negative 
symptoms. However, in many cases cognitive symptoms persist and may 
even be heightened (11). 
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Figure 2. Chart of symptom subsets associated with schizophrenia as defined by the 
NIMH. 
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1.3  Epigenetics & Chromatin Remodeling 
The definition of epigenetics has evolved and now refers to changes across the 
genome that regulate gene transcription without modification of the underlying genome 
sequence. Epigenetic changes such as histone modifications such as DNA methylation, 
acetylation, and deacetylation are potentially heritable. However, the new focus of 
epigenetics is the effect it has on drug treatment and factors that may play in brain 
function (3, 8, 28, 29).  
In eukaryotic cells, DNA is packaged into a nucleoprotein complex defined as 
chromatin. The basic unit of chromatin is a nucleosome, each of which contains 147 
base pairs of DNA wrapped twice around an octamer of core histone proteins, including 
H2A, H2B, H3, and H4. Histones are proteins that have a globular domain and amino-
terminal tail. Chromatin manifests in open and closed structural states. In the open 
state, the DNA wrapped around histones becomes unwound and is accessible to 
transcriptional machinery. Conversely, histones in the closed state are tightly wound 
with DNA, which cannot be transcribed. (8). Histone acetylation results in the open form 
of chromatin (euchromatin), while histone deacetylation has the opposite effect and 
suppresses DNA transcription (18, 23). 
There are four classes of histone deacetylases (HDACs), referred to as Class I - IV. 
Each class includes different subsets of HDACs. The focus of this study is HDAC2, 
which is a Class I HDAC. Class I HDACs, specifically HDAC1 and HDAC2, are believed 
to be responsible for most changes in histone acetylation. The activity of HDACs are 
regulated by binding of corepressors and post-translational modifications (5, 7, 23).  
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Figure 3. Pictorial depiction of the epigenetic mechanisms underlying histone 
acetylation and deacetylation 
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Figure 4:  Schematic model of improved antipsychotic drug action by HDAC2 
inhibition (10) 
 
A. Activation of 5-HT2A by the endogenous neurotransmitter serotonin represses HDAC2 
promoter activity, B. Atypical antipsychotic drugs reverse the 5-HT2A-dependent repression of 
HDAC2, an effect that is associated with increased HDAC2 binding and repressive histone 
modifications at the promoter regions of synaptic plasticity genes, C. Inhibition of HDAC2 by 
vorinostat prevents these atypical antipsychotic drug-dependent repressive histone 
modifications, which improves the therapeutic efficacy. 
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HDACs are expressed differently in various cell types, including neurons, 
oligodendrocytes, and astrocytes. However, HDACs have been shown to be expressed 
primarily in neurons (8, 9). 
1.4 Therapeutic potential of HDAC inhibitors 
Chronic administration of atypical antipsychotics, such as clozapine and 
risperidone, have been shown to downregulate the gene that encodes the 
metabotropic glutamate 2 receptor (mGlu2) via histone deacetylation. Chromatin 
immunoprecipitation assays have shown that this deacetylation results from HDAC2 
binding to the promoter region of the mGlu2 gene thereby decreasing the levels of 
histone 3 acetylation, an epigenetic modification that is normally pro-transcriptive 
(11). 
The mechanism by which this change occurs begins with a decrease in histone 
acetylation at the promoter region of the 5HT2A gene caused by clozapine. This 
ultimately leads to increased HDAC2 expression and the subsequent binding of 
HDAC2 at the mGlu2 promoter. The net effect of this process is decreased 
expression of mGlu2. The significance of this finding was further explored using 
mouse models. Mice that were virally induced to over express HDAC2 in the frontal 
cortex, thereby decreasing mGlu2 transcription, showed an increase in psychosis-
like behavior. 
In the same study, researchers investigated the effect of the HDAC inhibitor, 
suberoylanilide hydroxamic acid (SAHA), also known as vorinostat. SAHA was 
injected into mouse prefrontal cortexes, resulting in an increase in mGlu2 and 
mGlu3 expression. When SAHA was administered chronically along with clozapine,  
13	  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Structure of SAHA/vorinostat. 
http://www.reagentsdirect.com/index.php/small-molecules/small-molecules-
1/saha/saha-vorinostat.html 
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SAHA blocked the downregulating effect of clozapine on mGlu2. Furthermore, it 
enhanced the ability of clozapine to ameliorate schizophrenia-like symptoms 
induced by administration of the hallucinogen DOI (1-(2,5-dimethoxy-4-iodophenyl)-
2-aminopropane) or another psychotomimetic drug, MK-801. For these reasons, 
HDAC inhibitors are potentially promising as an adjunctive therapy in the treatment 
of schizophrenia (11, 12). 
2 Previous work in the Maeso Lab 
Previous work in the Maeso lab  included screening for genes differentially 
expressed in mouse prefrontal cortex models following administration SAHA (20 
mg/kg) or saline for 21 days. Two groups of mice with three independent biological 
replicates per group were used for the microarray study, totaling 6 microarrays. Mice 
were sacrificed one day after the last injection. All animals were handled, treated, 
and sacrificed at the same time and under the same conditions. RNA and array 
processing was also performed at the same time.  RNA was extracted from the 
mouse frontal cortex using the RNeasy lipid tissue mini kit (Qiagen). 
 Labeling and hybridization of the samples to Mouse Gene 1.0 ST expression 
chip (Affymetrix) were performed by the Mount Sinai Microarray Shared Resource 
Facility using standard methodology. Data quality control was performed using the 
Affymetrix Expression Console software. Areas under the Receiver Operating 
Characteristic curve (ROC) discriminate between positive control probesets and 
negative control probesets (pos.vs.neg.auc). All samples were found to be of very 
high quality, with pos.vs.neg.auc metric &gt; 0.89 (0.5 being no better than chance 
and 1.0 being perfect distinction), and no outlier was detected. Probe set 
16	  
 
summarization, background correction and normalization were then carried out in 
the same software using default settings. Normalized data were analyzed in 
MultiExperiment Viewer software and differential gene list was generated using the 
Significance Analysis of Microarrays algorithm; Cutoff was chosen so that the false 
discovery rate does not exceed 12%. As a result, we obtained a final list of 284 
probe sets, corresponding to 124 RefSeq genes. Pathway enrichment analysis was 
performed using the Ingenuity Pathway Analysis, with a score threshold (an 
adjusted Fisher Exact p-value) of 0.05 (Supplementary Fig. 19). The microarray 
data discussed in this paper have been deposited in NCBI’s Gene Expression 
Omnibus (GEO, http://www.ncbi.nlm.nih.gov/geo). The data analysis criteria used 
for our study are recommended by the MicroArray Quality Control project, and these 
criteria have been validated to provide a high degree of intersite reproducibility and 
inter- and intraplatform reproducibility. 
 Microarray analysis showed that animals receiving SAHA treatment had 
remarkedly increased gene expression when compared with controls (Figure 6). 
Because the method of microarray analysis is not as accurate and can result in false 
positives. Because the method of microarray analysis is not as accurate and can 
result in false positives, various genes were chosen to replicate the experiment 
using RT-qPCR to determine whether in fact there was differential expression 
(Table 1). 
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Figure 6:  Microarray Heatmap 
 
Analysis of gene expression after chronic SAHA. Heat map shows 
differentially expressed genes in frontal cortex of mice chronically (21 days) treated with 
SAHA (20 mg/kg) versus control (three mice per group). Mice were sacrificed one day 
after the last injection.  
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Table 1:  Table of genes 
Gene Function 
Lpar2 • Lysophosphatidic acids (LPAs) are bioactive lipids that function as 
lipid-signaling molecules of different chain lengths and 
phosphorylation and are expressed by a wide array of immune 
cells (20). 
Ankrd9 • involved in mediating protein-protein interactions in a variety of 
different families of proteins (NCBI). It is also involved in various 
cell fxns including intracellular adaptor, trafficking, transcription, 
signal transduction, and stress response (Wang et al., n.d.). 
Efnb1 • The protein that is encoded by this gene may play role in cell 
adhesion as well as the function and development or even the 
maintenance of the nervous system (NCBI). 
S100Z • S100 proteins have regulatory effects on a number of different cell 
types such as microglia, neutrophils, lymphocytes, neurons, 
astrocytes, schwann cells, and more. 
• Therefore they participate in both innate and adaptive immune 
responses, tissue development and repair, cell migration, and 
tumor cell invasion (12). 
Aqp1 • encodes a functioning water channel protein that permits passive 
transfer of water osmotically (NCBI). 
Abhd16a • Abhydrolase domain containing 15A is included in a cluster of 
genes localized for tumor necrosis factor alpha and beta. The 
protein this gene encodes is thought to be associated with 
immunity as this gene is within the human major histocompatibility 
complex class III region (NCBI). 
 
Eif5 • eukaryotic translation initiation factor promotes hydrolysis of GTP 
to allow joining of 60S ribosomal subunit with 40S subunit resulting 
in the functional 80S ribosomal initiation complex, which is then 
active (NCBI) 
Gbf1 • Golgi brefeldin A resistant guanine nucleotide exchange factor 1 is 
involved in regulating proteins to membranes by mediating the 
GDP to GTP exchange. It also plays a role in vesicular trafficking 
when in the golgi apparatus and is a host factor for viral replication 
(NCBI). 
Itch • Itch E3 ubiquitin protein ligase plays a role in cellular processes 
such as erythroid and lymphoid cell differentiation and further 
regulates immune responses (NCBI). 
Ssr3 • The signal sequence receptor is a membrane receptor that 
translocates proteins across the ER membrane (NCBI). 
Ube2g1 • Proteins with ubiquitin are important for targeting abnormal 
proteins for degradation (NCBI). 
Homer1 • Homer is a scaffolding protein that regulates mGluR signaling. 
20	  
 
Long variants of this protein link mGluR and its mediators by their 
EVH1 domains. The shorter variants are unable to provide this 
linkage and act as a negative protein, disrupting the crosslink 
action via mGlur-Homer signaling.  
Hdac1 • Histone deacetylase 1 encodes a protein that interacts with 
retinoblastoma tumor-suppressor protein and controls cell 
proliferation and differentiation. This results in a regulation on cell 
growth and apoptosis (NCBI).  
Hdac2 • Histone deacetylase 2 is part of a family of HDACs that 
deacetylate lysine residues at the N-terminal regions of core 
histones. The protein this gene encodes forms transcriptional 
repressor complexes via association with different proteins (NCBI). 
Hdac5 • The protein encoded by histone deacetylase 5 is part of class II 
HDACs and functions to repress transcription when it is tethered to 
a promoter (NCBI). 
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Table 2:  Table of primers 
Homer1 Forward AGCAGAAGGAAGGCTTGACT 
Homer1 Reverse CACGGTACGGCCAATAACTA 
Hdac5 Forward ACTCCTCTGCACAGCATCC 
Hdac5 Reverse CTGGGGCTACCTCCACCT 
Hdac1 Forward GGCACCAAGAGGAAAGTCTG 
Hdac1 Reverse CAAATTGTGAGTCATGCGGA 
Hdac2 Forward CATGGCGTACAGTCAAGGAG 
Hdac2 Reverse TCATCCGGATTCTATGAGGC 
Abhd16a Forward  GCAGCATCTCAACCTCAACA 
Abhd16a Reverse GGTGGTGATGATCTCGTCCT 
Gbf1 Forward CCCAGAGATACCCTCAGAAATGG 
Gbf1 Reverse TCTTGGGCAGGACTCAGTTTG 
Eif5 Forward AGGAAGAAGATGAAGACGAAAATATTG 
Eif5 Reverse TGTTGTCAGACTTCACAGTTTCAACT 
Itch Forward CATCGAAAAAGTTGGCAAAGAA 
Itch Reverse GGTCCAGGCGGTTAAAACAA 
Ssr3 Forward AGGATTTCAGCCGCAACCT 
Ssr3 Reverse CGCGTTCCCGAAGAACAG 
Ube2g1 Forward CCGGCCTCCTAAAATGAAATT 
Ube2g1 Reverse GCAAACATCACCATTTTTATCAACA 
Aqp1 Forward CTAGTGGGTCTGCCCGTGTAA 
Aqp1 Reverse GGAGACTGGAGGACCGAAATAA 
22	  
 
Ankrd9 Forward CCTGGCAGTGCGAGATCAG 
Ankrd9 Reverse GCTTCGCTGGCACGTATGT 
Efnb1 Forward TGTGTCGCACCCGCACTA 
Efnb1 Reverse GGGTGTCACAGCATTTGGATCT 
Lpar2 Forward GGGCCAGTGCTACTACAACGA 
Lpar2 Reverse AGCTCCTTGCCGCTGTTATTAT 
S100z Forward CGCATCTTCCACCGGTACTC 
S100z Reverse CCCCCTTGTTGAGCTTGAAC 
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Chapter 2:  Materials and Methods 
2.1 Wildtype and HDAC2 Conditional Knockout Mice 
 Treatment mice included wildtypes of the strain C57BL/6 (Taconic) and HDAC2 
conditional knockout mice. Animals were housed with a 12h light/dark cycle and were 
provided with access to food and water. Pups were weaned from their mothers after 21 
days and were then housed in cages of 3-5 mice.  All mice used were 6-8 weeks of age 
at the time of treatment and male. 
 Hdac2 KO mice were obtained from The Jackson Laboratory (stock number:  
022625). Heterozygous Hdac2 +/− mice were intercrossed to generate Hdac2−/− mice 
on a C57BL/6 background. Homozygosity of the Hdac2-null allele resulted in either 
embryonic lethality or partial lethality during the first few days postnatal as a result of 
proliferation defects and impaired development (data not shown). These findings are 
consistent with some but not all of the prior descriptions of global Hdac2 gene deletion. 
Based on this, we therefore used CaMKIIα-Cre transgenic mice on a C57BL/6 
background, in which Cre recombinase is efficiently expressed in combination with 
conditional loss of function of Hdac2 alleles. In mice, CaMKIIα is expressed postnatally 
in forebrain glutamatergic pyramidal neurons, beginning 10–14 d after birth. To delete 
HDAC2 function specifically in forebrain glutamatergic pyramidal neurons, we bred 
homozygous Hdac2loxP/loxP mice to the CaMKIIα-Cre transgenic line. In contrast to 
the global deletion of HDAC2, Hdac2loxP/loxP:CaMKIIα-Cre (Hdac2- cKO) mice were 
viable and did not display any gross histological or developmental abnormality (data not 
shown). Hdac2loxP/loxP:CaMKIIα-Cre mice were born at near expected Mendelian 
ratios (data not shown. Genomic DNA was isolated from ears for genotyping by PCR  
24	  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7:  Flow chart of overall procedure 
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Figure 8:  Strategy for deleting forebrain pyramidal HDAC2 function (h). Western blots 
showed decreased HDAC2 protein levels in the frontal cortex, but not cerebellum, of 
Hdac2-cKO compared to control littermates (n = 4–6 mice per experimental condition) (l, 
m). (10) 
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analysis. The primer sequences used were as follows:   Hdac2loxP/loxP: Hdac2 wt 
allele forward	  (5′-GCACAGGCTACTACTGT GTAGTCC-3′), Hdac2loxP mutant allele: 
forward (5′GTCCCTCGA CCTGCAGGAATTC-3′), Hdac2loxP mutant allele reverse (5′-
CCACCACTGACATGTACCCAAC-3′); CaMKII-Cre, transgene forward (5′-
GCGGTCTGGCAGTAAAAACTATC-3′), transgene reverse 
(5′GTGAAACAGCATTGCTGTCACTT-3′); internal positive control forward (5′ 
CTAGGCCACAGAATTGAAAGATCT-3′), internal positive control reverse (5′ 
GTAGGTGGAAATTCTAGCATCATCC-3′). 
2.2 Chronic treatment with saline or SAHA 
To test the effect of chronic SAHA treatment on gene expression, both wildtype 
mice and HDAC2KO mice were injected (i.p.) once a day for 21 days with SAHA 
(20mg/kg; obtained from Cayman Chemical). SAHA was suspended in a minimal 
amount of DMSO and brought up to volume with saline on the day of each injection. 
Control mice were injected chronically with vehicle (saline). On the day after the last 
injection, the mice were sacrificed via cervical dislocation, and the prefrontal cortices 
were dissected and stored at –80°C until ready for mRNA isolation.  
2.3 Tissue Homogenization & mRNA isolation 
 The brain tissue was purified using TRIZOL reagent (1 mL per sample) as the 
lysis buffer and further isolated via the RNAeasy lipid kit (Qiagen). The brain tissue was 
sheared using an 18-gauge needle attached to a 5-ml syringe. Isolated mRNA was 
measured using the Nanodrop 1000 software (Thermo Fisher). 
RNA ISOLATION PROTOCOL 
 
NOTES 
De-contaminate the work area, all work tools, and their surfaces of RNase using 70% EtOH 
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followed by RNaseZap. Lay out absorbency paper.  
Exclusively use filter-tips. 
Chill centrifuge to 4°C. 
Get a bucket of ice. 
MATERIALS 
• RNaseZap 
• 70% EtOH 
• benchtop absorbency paper 
• RNeasy Lipid Tissue mini kit 
• 1.5 ml microfuge tubes 
• 18-gauge needles 
• 5-ml syringes 
• RNase-free DNase kit (Qiagen) 
• DEPC-treated water 
• Kim wipes 
PROCEDURE 
Tissue Homogenization & RNA Isolation  
1. Retrieve brain tissue and place on ice. 
2. Add 1 ml QIAzol reagent per sample. 
3. Homogenize tissue using an 18-gauge needle attached to a 5-ml syringe. Shear 
tissue upwards of 30 times until no more tissue chunks can be seen.  
a. Never recap the needle. Dispose of used syringes in sharps container. 
4. Transfer to pre-labeled 1.5 microfuge tubes. 
5. In the fume hood (which has been de-contaminated with RNaseZAP), add 200 µl 
chloroform, secure the cap, vigorously shake for 15 secs, and incubate at room 
temperature for 3 mins. 
6. Centrifuge at 12,000g for 15 mins at 4°C.  
7. While waiting, prepare DNase I incubation mix. For each sample, add 10 µl DNase I 
stock solution to 70 µl Buffer RDD. Mix by gently inverting the tube. 
a. RDD is supplied with the RNase-Free DNase kit.  
b. DNase I is sensitive to physical denaturation, so mixing should only be carried 
out by gently inverting the tube. Never vortex. 
8. Transfer the upper, aqueous phase to a new 1.5 ml microfuge tube. 
a. Do not transfer any interphase solids. 
9. Add 1 volume (about 500 µl) of 70% ethanol, and mix thoroughly by vortexing. Do not 
centrifuge. 
10. Transfer up to 700 µl of the sample to an RNeasy Mini spin column placed in a 2 ml 
collection tube. Centrifuge for 15 secs at 8,000g at room temperature. Discard the 
flow-through. Repeat until all sample has been applied to the column. 
11. Wash the membrane with 350 µl Buffer RW1 and centrifuge for 15 secs at 8,000g 
(10,000 rpm). Discard the flow-through. 
12. Add 80 µl DNase I incubation mix (from Step 7) directly to the RNeasy spin column 
membrane, and incubate at room temperature for 15 min.  
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13. Wash with 350 µl Buffer RW1, and centrifuge for 15 secs at 8,000g. Discard the flow-
through. 
14. Wash with 500 µl Buffer RPE, and centrifuge for 15 secs at 8,000g. Discard the flow-
through and replace collection tube. 
15. Wash with 500 µl Buffer RPE, centrifuge for 3 min at max speed to dry column. 
a. Any carryover EtOH will interfere with downstream assays.  
16. Carefully remove spin column from the collection tube so column does not contact the 
flow-through. 
17. Place the spin column in a new, pre-labeled 1.5 ml collection tube. Add 30 µl RNase-
free water (provided in kit) directly to the spin column and incubate at room 
temperature for 2 mins. Elute by centrifuging for 1 min at 8,000g.  
a. To increase yield, repeat previous step using 20 µl of RNase-free water. 
18. Place purified RNA on ice. Measure concentration and purity by NanoDrop.  
 
2.4 Reverse Transcription Reaction 
 Each sample of the same treatment condition was normalized to the lowest 
amount of mRNA obtained via the nanodrop software to ensure that the same amount 
of mRNA was to be compared between samples. The RT reaction was carried out using 
oligo dt, DTT, and dNTPs, followed by a master mix of 5x buffer, Superscript III, and 
RNAse out.  
2.5 RT-qPCR 
cDNA obtained from the reverse transcription reaction was diluted to a 1:40 
dilution for the RT-qPCR reaction. The QuantFlex Studio 6 machine was used to carry 
out qPCR for a total of 10 uL including 4uL of cDNA, 1 uL of primer, and 5 uL 
PowerUp™ SYBR™ Green Master Mix (Thermo Fisher Scientific, Catalog 
number:  A25777) per reaction well. 384 Well plates were used. In Real-Time qPCR, 
a fluorescent reporter molecule is utilized to monitor the progression of the reaction. For 
this study, SYBR green was used as the reporter molecule (Figure 7), which allows the 
quantification of the template to be based on the fluorescence signal during the 
exponential phase of amplification. As each cycle of amplification is carried out, there 
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will be an increase in fluorescence intensity, which is proportional to the increase in 
concentration of the amplicon.  
A method of confirmation to verify specific amplification calls for analysis of the 
melt curve. Each reaction was carried out in quadruplicates, meaning there were 4 wells 
with the same conditions of cDNA, SYBR green, and primer. The melt curve should 
show a single homogenous peak, which would indicate specific amplification. We first 
tested the primers to ensure specific amplification by examining the melt curves. After 
ensuring that each primer provided a homogenous peak, indicative of specific 
amplification, we went on to test the primers on the wildtype and HDAC2 KO samples in 
the experiment. 
The amplification plot is graphically depicted as fluorescence vs cycle number. 
The threshold cycle (Ct) value shows the threshold fluorescence level. Once the plot 
crosses this threshold level, the subsequent Ct values can be correlated to the starting 
concentration of the sample. (Figure 8).  
2.6 Statistical Methods 
 Ct Medians obtained from RT-qPCR were processed to determine mRNA level 
fold change. Significance was tested using a two-tailed t-test (GraphPad PRISM). 
Values are shown in Tables 3.1 and 3.2 for wildtypes and conditional Hdac2 KO mice, 
respectively.  
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Figure 9:  Pictorial depiction of SYBR green binding to the amplicon during RT-
qPCR  
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Figure 10:  Pictorial description of RT-qPCR amplification plot 
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Figure 11:  Pictorial depiction of Melt Curve to confirm specific amplification 
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Chapter 3:  Results 
 
The results are graph representations of a two-tailed t-test conducted by the 
PRISM software. Upon analysis, it was found that in wildtypes treated with SAHA vs 
vehicle, the genes, ITCH and UBE2G1, were downregulated when treated with SAHA 
(Figure 12 D,E). The genes ABHD16A and GBF1 were both upregulated upon 
treatment with SAHA in wildtype mice (Figure 12, AB). HDAC2 was significantly 
downregulated in wildtype mice treated with SAHA as compared to vehicle (Figure 14, 
C). 
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TABLE 3.1: TWO-TAILED T-TEST COMPARING QUANTITATIVE EXPRESSION 
OF GENES IN WILD TYPE MICE TREATED WITH VEHICLE VS SAHA 
 
GENE Vehicle treated mice N SAHA treated mice N P value  
ABHD16A 1.000 ± 0.08611 12 1.322 ± 0.08362 12 0.0137 * 
ANKRD9 1.000 ± 0.4725 12 2.888 ± 0.8591 12 0.0672  
AQP1 1.000 ± 0.2758 12 1.071 ± 0.1724 12 0.8302  
EFNB1 1.000 ± 0.2012 12 0.9913 ± 0.06505 12 0.9675  
EIF5 1.000 ± 0.04188 12 0.8799 ± 0.1456 12 0.4452  
GBF1 1.000 ± 0.06942 12 1.319 ± 0.1291 12 0.0403 * 
HDAC1 1.000 ± 0.1093 12 0.8623 ± 0.09276 12 0.3470  
HDAC2 1.000 ± 0.1148 12 0.6699 ± 0.05243 12 0.0158 * 
HDAC5 1.000 ± 0.1371 12 1.043 ± 0.1291 12 0.8224  
HOMER1 1.000 ± 0.07692 12 1.195 ± 0.1431 12 0.2429  
ITCH 1.000 ± 0.05122 12 0.5699 ± 0.1277 12 0.0040 * 
LPAR2 1.000 ± 0.1155 12 1.130 ± 0.1101 12 0.4258  
S100Z 1.000 ± 0.1862 12 1.181 ± 0.1818 12 0.4943  
SSR3 1.000 ± 0.3114 12 0.6778 ± 0.1556 12 0.3612  
UBE2G1 1.000 ± 0.05237 12 0.7999 ± 0.06986 12 0.0319 * 
Data are shown as mean ± SEM. *p<0.05. Student’s t-test. 
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TABLE 3.2: TWO-TAILED T-TEST COMPARING QUANTITATIVE EXPRESSION 
OF GENES IN HDAC2 KNOCKOUT MICE TREATED WITH VEHICLE VS SAHA 
GENE Vehicle treated mice N SAHA treated mice N P value  
ABHD16A 1.000 ± 0.1940 6 1.080 ± 0.1791 6 0.7686  
ANKRD9 1.000 ± 0.2901 6 1.107 ± 0.09678 6 0.7329  
AQP1 1.000 ± 0.3560 6 0.6106 ± 0.04504 6 0.3034  
EFNB1 1.000 ± 0.1765 6 1.325 ± 0.3082 6 0.3816  
EIF5 1.000 ± 0.2382 6 0.8960 ± 0.1188 6 0.7042  
GBF1 1.000 ± 0.1797 6 1.210 ± 0.2726 6 0.5344  
HDAC1 1.000 ± 0.07734 6 1.067 ± 0.1578 6 0.7094  
HDAC2 1.000 ± 0.1959 6 2.014 ± 0.8279 6 0.2608  
HDAC5 1.000 ± 0.1329 6 3.972 ± 2.455 6 0.2546  
HOMER1 1.000 ± 0.1217 6 1.156 ± 0.3353 6 0.6717  
ITCH 1.000 ± 0.04153 6 1.193 ± 0.1855 6 0.3339  
LPAR2 1.000 ± 0.2486 6 0.8205 ± 0.1457 6 0.5473  
S100Z 1.000 ± 0.4103 6 0.9759 ± 0.2474 6 0.9609  
SSR3 1.000 ± 0.1564 6 1.325 ± 0.2614 6 0.3116  
TBKBP1 1.000 ± 0.2087 6 2.356 ± 1.239 6 0.3057  
UBE2G1 1.000 ± 0.09328 6 1.343 ± 0.1317 6 0.0598  
Data are shown as mean ± SEM. Student’s t-test. 
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Figure 12:  Differential expression of genes was identified by RT-qPCR in wildtypes 
and HDAC2 KO mice treated with vehicle vs SAHA. Increased gene expression of 
ABHD16A (A) and GBF1 (B) in wildtype mice treated with SAHA. Decreased 
expression of ITCH (C) and UBE2G1 (D) in wildtype mice treated with SAHA. 
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Figure 13:  A trend to increased gene expression of ANKRD9 in wildtype mice 
treated with SAHA but not in HDAC2 KO mice 
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Figure 14: Significant decrease in expression of HDAC2 when wildtype mice were 
chronically treated with HDAC inhibitor, SAHA. 
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Chapter 4:  Discussion 
 
4.1 Implications of this study 
The results show the therapeutic potential of SAHA as it is implicated in some genes 
having neurological functioning. Both ITCH and UBE2G1 showed downregulation when 
treated with SAHA in wildtypes, but not KO mice. Similarly, both ABHD16A and GBF1 
showed upregulation in SAHA treated wildtypes, but not KO mice. There was significant 
decreased expression of HDAC2 in wildtype mice treated with the HDAC inhibitor, 
SAHA but not HDAC5 or HDAC1. This provides support that these genes are 
differentially expressed in an HDAC2 dependent manner. The genes that were deemed 
insignificant by RT-qPCR that showed upregulation when tested by microarray analysis 
could be for a number of reasons. The experiments conducted at Mt. Sinai previously 
were produced in the year 2010. Although the same strain, sex, and age of mice were 
used in the experiments conducted at VCU, there easily may be individualized 
differences from sample to sample. Of the genes that previously showed differential 
expression via microarray analysis ANKRD9 (p<0.0672) showed an upward trend in 
wildtypes treated with SAHA when compared to vehicle. However, a two-tailed t-test 
deemed the results insignificant for this gene. Further experiments would need to be 
carried out to assess whether other genes may possibly be significantly affected.  
4.2 Future directions 
Future goals stemming from this study include screening more of the target 
genes differentially expressed from the microarray analysis. Further, recreating the 
experiment with a higher sample size of wildtype mice and HDAC2KO mice would be 
required. It would be worth researching sex differences between male and female mice 
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as the work conducted so far has been done exclusively using male mouse models. 
Additionally, treating two separate cohorts in conjunction with clozapine and SAHA 
respectively may shed more insight into which exact genes overlap in terms of 
differential regulation between both treatment types. 
 Of the genes expressed, UBE2G1 encodes a protein that is a ubiquitin and is 
important for targeting abnormal genes for degradation. A study showed that 
olanzapine, another second generation antipsychotic, upregulated the expression of 
various genes including several ubiquitin-conjugating enzymes, including UBE2G1 (16). 
The study did not test the effect of clozapine on UBE2G1 levels. It would be worth 
analyzing the expression of this gene in models treated with clozapine, especially 
because this gene was down-regulated in SAHA treatment. 
Furthermore, the gene ITCH, has been implicated as a regulator for various 
neurodevelopmental and neurodegenerative disorders. The protein, ITCH, catalyzes the 
degradation of multiple substrates via autophagy and results in regulating molecular 
pathways in the brain such as synaptogenesis, synaptic connections, and axon and 
dendritic branching.  
Golgi brefeldin A resistant guanine nucleotide exchange factor 1 (GBF1) is involved 
in regulated proteins to membranes via GDP and GTP exchange. GBF1 typically 
functions as a transport between the endoplasmic reticulum and golgi apparatus and 
further recruits other GEFs, such as BIG1 and BIG2 to the trans-golgi network (TGN). A 
study showed that treatment of neurons with an inhibitor of BIG1 resulted in a significant 
decrease in GABAA  receptors at the neuronal surface of bovine brain. This suggests 
the important function of theses GEFs in trafficking GABAA receptors to the cell surface. 
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Mutations in BIG2 have been previously reported to hinder neural progenitor 
proliferation and migration in the human cerebral cortex (14). Due to these findings, it 
would be worth while to test previous samples to examine whether the expression of 
BIG1 and BIG2 also change along with GBF1.  
ABHD16A is the primary brain phosphatidylserine hydrolase, which generates 
ABHD12. Mutations in ABHD12 are involved in human causes of the neurodegenerative 
disorder PHARC (polyneuropathy, hearing loss, ataxia, retinosis pigmentosa, and 
cataract) (15, 19). Because of this implication of ABHD16A’s involvement in another 
neurodegenerative disorder, it further warrants study in relation to schizophrenia. 
Ankrd9, the gene that had an upward trend, is involved in lipid metabolism. More 
experiments would need to be carried out to see if that metabolism has any correlation 
to the brain, a lipid heavy organ (Wang). 
A recent finding implicated epigenetic dysfunction associated with schizophrenia. A 
study analyzed postmortem brains from patients diagnosed with schizophrenia and 
found these samples were deficient in an extracellular matrix protein, reelin, which 
contains several sites for DNA methylation. HDACs increase the expression of this 
protein, supporting that the regulation of this protein is under epigenetic control (1).  
The gene encoding the protein SMARCA2, a part of the SWI/SNF chromatin-
remodeling complex has been associated with schizophrenia in genome-wide-
association studies. Polymorphisms in this gene produce a change in gene expression 
or the amino acid sequence (2). 
It is reported that histone acetylation increases neuronal activity and may sustain 
changes in gene expression associated with synaptic plasticity and memory. In mouse 
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models of Alzheimer’s disease associated cognitive impairment and neurodegeneration, 
HDAC2 levels were increased in both the hippocampus and prefrontal cortex. This 
upregulation of HDAC2 corresponded with greater binding of HDAC2 to synaptophysin 
and Bdnf, genes associated with synaptic plasticity and learning (6). 
Acetylation in the prefrontal cortex region was studied in vitro and in mouse models treated 
with either vehicle, Cpd-60, or SAHA, both of which are HDAC inhibitors. Both of these HDAC 
inhibitors increased acetylation in the prefrontal cortex by 1.5-2.0 fold, supporting that both of 
these suppress HDAC activity in the brain following administration (Schroeder) 
Dr. Gonzalez-Maeso is in collaboration with a brain bank in Spain, which has 
samples of post mortem human brain of control subjects, untreated schizophrenics, and 
treated schizophrenics. Although, we do not have access to samples treated with 
SAHA, it would be worthwhile to look at the expression of these specific genes in 
subjects treated with atypical antipsychotics to see if they are expressed in the opposite 
direction as what we have found in mouse brain models treated with SAHA. 
Furthermore, Dr. Gonzalez-Maeso, is in collaboration with VCU School of Medicine 
for an ongoing clinical study. Currently, they are in the stage of recruiting patients 
diagnosed with schizophrenia who are taking atypical antipsychotic medications. These 
patients will receive either SAHA or placebo. To look at the expression of various genes 
that have been implicated as differentially expressed in mouse models, an option would 
be to test the peripheral blood tissue of these patients for those specific genes post 
treatment with SAHA. 
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